Drugs / Autologous thyTreg
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04924491 | Sep 2020 → Dec 2026 expected | — | Rafael Correa-Rocha | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous thyTreg | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04924491 ↗ |
| Modality | Cell therapy | “Our thyTreg product has been approved by the Spanish Drug Agency (AEMPS) to be administered as cell therapy.” PMID 35651624 ↗ May 2022 |